| HOME >> BIOLOGY >> TECHNOLOGY |
Turnover Increased by 37%
HONG KONG, April 22 /Xinhua-PRNewswire/ -- Fufeng Group Limited ("Fufeng" or "the Company", together with its subsidiaries collectively known as "the Group"; HKEx: 546), a leading vertically integrated manufacturer of corn-based biochemical products in China, announced its annual results for the year ended 31 December 2007.
During the year, driven by the increased sales volume of major products, the Group's turnover increased to RMB2,445.7 million, representing an increase of 37% compared to 2006. However, with the decrease in the average selling prices (ASP) of the Group's major products and the increase in the cost of raw materials, especially corn kernel, the Group's gross profit dropped to RMB249.7 million. The increase in transportation, administrative expenses also further lowered the Group's profitability. Fufeng recorded a profit attributable to shareholders for 2007 of approximately RMB 45.1 million. Its earnings per share for 2007 amounted to RMB 2.8 cents.
Commenting on the results, Mr. Li Xuechun, Chairman of Fufeng said, "Despite the challenging market conditions in 2007, the Group managed to maintain its leading position in the corn-based fermentation industry. During the year, we strived to capture the opportunity brought by MSG and glutamic acid industry consolidation and actively expand our market, our market share in the sector surged significantly to 23% in 2007 from 17% in 2006. As for xanthan gum, the Group actively expanded export business, the export portion of xanthan gum increased from 65% to 83%. Other than better selling price, the Group can also enlarge our market share in xanthan gum through exporting products."
During the period, the Group posted a healthy increase for its MSG
segment. The sales volume of MSG increased by nearly 200% to 91,850 tonnes,
this proves the Group's decision to shift its focus from glutamic acid to
MSG production. Besides, fertili
'/>"/>
| SOURCE Fufeng Group Limited Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |